6BULGAHO A.Misoprostol for prevention of postpartum hemorrhage[J].Inter J Gynecol Obstet rics,2001,73:110-110.
二级参考文献25
1[1]WHO.Global estimates of maternal mortality for 1995:results of an in-depth review analysis and estimation strategy statement.Geneva:WHO(2001)
2[2]Burrows RF,Kelton JG.Pregnancy in patients with idiopathic thrombocytopenic purpura:assessing the risks for the infant at delivery.Obstetric Gynecology Survey.1993,48(2):781
4[4]Wing DA,Paul RH,Millar LK.Usefulness of coagulation studies and blood banking in patents with symptomatic placenta previa.Am J Perinatal.1997;14(10):601
5[5]Burrpws RF.Hemotthagic complications in the obstetric patient.in Colman RW,Hemostasis and thrombosis,4th ed,Philadelphia:Lippincott Williams and Wilkins,2000,1045
6[6]Collaborative low-dose aspirin study in pregnancy collaborative group.CLASP.A randomized trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9364 pregnant women.Lancet,1994,343:619
7[7]WHO.Managing complications in Pregnancy and Childbirth:A Guide for Midwives and Doctors.Geneva:WHO(2000)
8[8]Naif RW,Chauhim SP,Chevalier SP,et al.Prediction of hemorrhage at Cesarean delivery.Obstetric Gynecology,1991,77(4):485
9[9]Bulgaho A.Misoprostol for prevention of postpartum hemorrhage.Inter J Gynecology and Obstetrics,2001,73(1):1
10[10]Prendiville WJ.Active versus expectant management in the third stage of labour. Cochrane Database Syst Rev.2001,(3):CD000007
